- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Short course of Apremilast and phototherapy combination not sufficient for psoriasis management
A combination of Phototherapy and apremilast was not effective for the management of Psoriasis Vulgaris as per a recent study that was published in The Journal of Dermatology.
Apremilast is an oral phosphodiesterase-4 inhibitor. Phototherapy and apremilast are commonly used in the management of moderate to severe Psoriasis Vulgaris. But the current evidence on the efficacy and safety of their combination is not sufficient. Hence researchers conducted a multicenter, randomized controlled study to compare the efficacy and safety between phototherapy as monotherapy and a combination of phototherapy and apremilast in patients with Psoriasis Vulgaris.
All the patients with moderate to severe Psoriasis Vulgaris were randomized to two groups of combination therapy with 29 participants and monotherapy with 13 participants. All patients underwent an 8-week phototherapy regimen comprising irradiation with narrowband UV-B. The patients in the combination group were also administered 10 mg to 60 mg of oral apremilast. Psoriasis Area and Severity Index (PASI) score from baseline to week 8 were the tools used to estimate the percentage of improvement. The percentage of patients who achieved ≥75% improvement in the changes in body surface area (BSA) and scores of EuroQol 5-dimensions 5-level, Dermatology Life Quality Index, and visual analog scale for pruritis from baseline to 4 and 8 weeks and any adverse events were also evaluated.
Findings:
- The combination group had significantly lower PASI scores at 4 and 8 weeks and more patients achieved a PASI score improvement of ≥75% at 8 weeks when compared with the monotherapy group.
- A significant decrease in BSA at 8 weeks was seen in both groups.
- There was no significant difference observed between the two groups, although the combination group tended toward a greater reduction in BSA.
- The intergroup differences in the changes at the three-time points were not significant.
- Adverse events were more frequent in the combination group than in the monotherapy group.
This study shows that an 8-week combined apremilast and phototherapy regimen may not be adequate in patients for improvements in their subjective assessment of psoriasis, and longer treatment periods may be necessary.
Further reading: Morita A, Yamaguchi Y, Tateishi C, Ikumi K, Yamamoto A, Nishihara H, Hayashi D, Watanabe Y, Watanabe Y, Maruyama A, Masuda K, Tsuruta D, Katoh N. Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis Vulgaris. J Dermatol. 2022 Sep 24. doi: 10.1111/1346-8138.16566. Epub ahead of print. PMID: 36151864.
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751